- Home
- DBRG vs KNSA Comparison
DBRG vs KNSA Comparison
Compare DBRG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- KNSA
- Stock Information
- Founded
- DBRG 1991
- KNSA 2015
- Country
- DBRG United States
- KNSA United Kingdom
- Employees
- DBRG N/A
- KNSA N/A
- Industry
- DBRG Real Estate Investment Trusts
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- KNSA Health Care
- Exchange
- DBRG Nasdaq
- KNSA Nasdaq
- Market Cap
- DBRG 2.3B
- KNSA 2.6B
- IPO Year
- DBRG 2009
- KNSA 2018
- Fundamental
- Price
- DBRG $12.47
- KNSA $39.06
- Analyst Decision
- DBRG Strong Buy
- KNSA Strong Buy
- Analyst Count
- DBRG 7
- KNSA 7
- Target Price
- DBRG $16.00
- KNSA $46.86
- AVG Volume (30 Days)
- DBRG 3.8M
- KNSA 458.1K
- Earning Date
- DBRG 10-30-2025
- KNSA 10-28-2025
- Dividend Yield
- DBRG 0.32%
- KNSA N/A
- EPS Growth
- DBRG N/A
- KNSA N/A
- EPS
- DBRG N/A
- KNSA 0.07
- Revenue
- DBRG $173,540,000.00
- KNSA $529,332,000.00
- Revenue This Year
- DBRG N/A
- KNSA $53.93
- Revenue Next Year
- DBRG $77.07
- KNSA $25.06
- P/E Ratio
- DBRG N/A
- KNSA $602.30
- Revenue Growth
- DBRG N/A
- KNSA 56.18
- 52 Week Low
- DBRG $6.41
- KNSA $17.82
- 52 Week High
- DBRG $17.33
- KNSA $39.79
- Technical
- Relative Strength Index (RSI)
- DBRG 54.26
- KNSA 61.74
- Support Level
- DBRG $11.71
- KNSA $38.02
- Resistance Level
- DBRG $12.91
- KNSA $39.45
- Average True Range (ATR)
- DBRG 0.82
- KNSA 1.11
- MACD
- DBRG -0.01
- KNSA -0.12
- Stochastic Oscillator
- DBRG 52.62
- KNSA 81.07
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.